Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cardix Therapeutics LLC currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by a distinct examiner within a distinct art unit. SAN MING R HUI is the busiest examiner for the portfolio, managing the 1 pending office action currently active for the company. This structure indicates that the company's current patent office interaction is concentrated on a single technical and administrative front.
The focus on 1 pending office action within the Biotechnology & Pharmaceuticals field allows for a highly specialized prosecution strategy. SAN MING R HUI is the primary point of contact for the company's current efforts, and the matter is situated within a distinct art unit. This lack of complexity in the current portfolio suggests that the company can prioritize the specific technical requirements of this individual application. By concentrating on the assigned examiner and art unit, the company avoids the need to manage diverse prosecution styles or conflicting office action timelines.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18630064 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18630064 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | HUI, SAN MING R | 1627 | Other | Non-Final OA | — | Pending | Apr 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCardix Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
San Ming R Hui has the most, with 1 of Cardix Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
